Join fellow healthcare professionals from across Australia for a peer-to-peer exchange of knowledge and clinical experience with biosimilar medicines. The video talk series, presentations and educational sessions provide insights into a range of areas for biosimilar medicines.

Dr Michael Coory, Department of Health

Listen to Dr Michael Coory, Department of Health, as he discusses how price disclosure works for biosimilar medicines and how this contributes to the sustainability of the Australian healthcare system

Biosimilar medicines in community pharmacy

This Q&A style discussion will look to further address the opportunities, concerns and practicalities of biosimilar medicines in community pharmacy.

Pharmacy Connect 2019: Biosimilar medicines in community pharmacy

This session will focus on biosimilar medicine use in a community pharmacy setting.

A FOCUS ON PEER-TO-PEER DISCUSSION AND EXPERIENCE

Join fellow healthcare professionals from across Australia for a peer-to-peer exchange of knowledge and clinical experience with biosimilar medicines.

Chief Pharmacist, Royal Marsden NHS Foundation Trust

Jatinder Harchowal provides an international perspective on the use of biosimilar medicines in the United Kingdom.

Chief Medical Officer, Australian Government

Professor Brendan Murphy is the Chief Medical Officer for the Australian Government and is the principal medical adviser to the Minister and the Department of Health.

Rheumatologist

Prof Bird has over twenty years’ experience in treating rheumatic disease, with particular expertise in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

Rheumatologist

A/Prof Östör MD, MA, MB BS, FRACP, FRCP, FRCP (Edin), is a Consultant Rheumatologist at Cabrini Medical Centre and Principle Investigator at Emeritus Research, Melbourne.

Haematologist

Prof Szer has particular expertise in malignant haematology and haemopoietic stem cell transplantation, which he established as a form of therapy in Victoria in the early 1980s.

Oncologist

Prof Zalcberg is Head of the Cancer Research Program in the School of Public Health and Preventive Medicine at Monash University.

Oncologist

Prof Clarke is a medical oncologist, pharmacologist and translational researcher with major clinical and research interests in gastrointestinal and thoracic cancers.

Dermatologist

Prof Sinclair is Professor of Dermatology at the University of Melbourne and Director of Epworth Dermatology. He is past-president of the Australasian Society for Dermatology Research.

Gastroenterologist

Dr Thin is a consultant gastroenterologist at Fiona Stanley Hospital, a position she has held for 8 years. Dr Thin is the lead clinical trials investigator for the IBD unit.

Gastroenterologist

Dr Ghaly is Head of the Inflammatory Bowel Disease Service and Staff Specialist at St. Vincent’s Hospital, Sydney. He is also a lecturer at the School of Medicine, UNSW Sydney.

Pharmacist

Executive Director Pharmacy and Redevelopment, North East Health, and owner and Director, David Ford Healthcare Consulting.

pharmacist

Barry has enjoyed a diverse career beginning in community pharmacy and moving into regional and remote hospital pharmacy in WA and far North QLD.

APP2018: Biosimilar medicines – the case for change

Dr Cornes is an oncologist in Bristol. He is part of the steering group for the European School of Oncology Working Party on the Access to Innovation in Cancer Treatment.

Pharmacy Connect 2018: Biologics and biosimilars

David Ford is a proven hospital executive with 30 years of clinical and management experience in hospital administration and department directorship.

APP2019: Biosimilar Update

A/Prof Ward continues to practice as a pharmacist and has research interests broadly related to the factors that influence variability in the safety and efficacy of medicines.

INTERDISCIPLINARY INSIGHTS

Listen to various experts discuss the potential cost savings and benefits of biosimilar medicines in Australia.

Interdisciplinary insights

Listen to various experts discuss the safety and efficacy of biosimilar medicines.

Interdisciplinary insights

Listen to various experts discuss the current clinical experience with biosimilar medicines.

A science success story

A biosimilar medicine is a highly similar version of an original brand of a biological medicine, which enters the market following the patent expiry of the original brand. Watch the video above to learn more.